| Increase in response rate by prolonged treatment with neoadjuvant letrozole. | |
| | |
MedLine Citation:
|
PMID: 18264759 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The aim of this study was to investigate the potential benefits of prolonged treatment with neoadjuvant letrozole. PATIENTS AND METHODS: About 182 consecutive patients have been treated in Edinburgh with neoadjuvant letrozole for 3 months or longer and 63 patients have continued on letrozole beyond 3 months. Outcomes are reported. RESULTS: Of the 63 patients who continued on letrozole, 38 patients took letrozole for more than 1 year and 23 took letrozole for more than 24 months. The median reduction in clinical volume in the first 3 months in these 63 patients was 52%. Similar reductions in median clinical volume were seen between three to 6 months (50%), 6-12 months and 12-24 months (medians 37 and 33%, respectively). At 3 months 69.8% of the 182 patients had a partial or complete response. The response rate increased to 83.5% with prolonged letrozole treatment. Continuing letrozole beyond 3 months increased the number of women who initially required mastectomy or had locally advanced breast cancer who were subsequently suitable for breast conserving surgery from 60% (81/134) at 3 months to 72% (96/134). Thirty-three women remain on letrozole alone (man age at diagnosis 83 years) and at 3 years the median time to treatment failure has not been reached. CONCLUSION: Continuing letrozole in responding patients beyond 3-4 months achieves further clinical reduction in tumour size. For elderly women with a short life expectancy letrozole alone may provide long-term disease control. |
| | |
Authors:
|
J Michael Dixon; Lorna Renshaw; E Jane Macaskill; Oliver Young; Juliette Murray; David Cameron; Gillian R Kerr; Dean B Evans; William R Miller |
Related Documents
:
|
19160429 - Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-... 19688629 - Atrophic acne scar treatment using triple combination therapy: dot peeling, subcision a... 2858709 - Controlled trial of tamoxifen as single adjuvant agent in management of early breast ca... 22038209 - The effect of early enteral nutrition on hyperthermic intraoperative intraperitoneal ch... 15838209 - Treatment of hypertrophic scars using a long-pulsed dye laser with cryogen-spray cooling. 10417579 - Pilot study evaluating topical onion extract as treatment for postsurgical scars. 20131119 - Patient satisfaction and clinical outcome following outpatient radiofrequency catheter ... 23357139 - Differences in the atherogenic risk of patients treated by lipoprotein apheresis accord... 18578959 - Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and st... |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2008-02-09 |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: 113 ISSN: 1573-7217 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2008-12-22 Completed Date: 2009-02-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 145-51 Citation Subset: IM |
Affiliation:
|
Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, Scotland. jmd@ed.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged, 80 and over Antineoplastic Agents / therapeutic use* Breast Neoplasms / drug therapy*, pathology, surgery* Combined Modality Therapy Disease Progression Drug Administration Schedule Female Humans Life Expectancy Mastectomy Mastectomy, Segmental Neoadjuvant Therapy Nitriles Time Factors Treatment Outcome Triazoles |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Nitriles; 0/Triazoles; 112809-51-5/letrozole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Racial and ethnic differences in mammography use among U.S. women younger than age 40.
Next Document: Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status:...